Search
  • sr0213

Promethean BioPharma supports the rescheduling of psilocybin and MDMA in Australia

Promethean BioPharma supports the work of Mind Medicine Australia and encourages their submissions to the Therapeutic Goods Administration in relation to the rescheduling of psilocybin and MDMA from Schedule 9 to Schedule 8.


For more information:

https://mindmedicineaustralia.org.au/


https://mindmedicineaustralia.org.au/wp-content/uploads/Mind-Medicine-Australia-Invitation-for-Rescheduling-Guide-27-August-2020.pdf


https://mindmedicineaustralia.org.au/wp-content/uploads/Mind-Medicine-Australia-Fact-Sheet-22-February-2021.pdf


Recent Posts

See All

Promethean BioPharma Limited has finalised the acquisition of Tcann Pty Ltd setting the stage for the execution of it's growth strategy.